Hyper-Immune Globulin
|
|
- Justin Jordan
- 5 years ago
- Views:
Transcription
1 Cytomegalovirus Cytogam Intramuscular GamaSTAN S/D Hepatitis B HepaGAM B HyperHEP B S/D Nabi - HB Rabies HyperRAB S/D IMOGAM Rabies - HT Tetanus HyperTET S/D (D) HyperRho S/D RhoGAM UF PLUS Rhophylac WinRho SDF
2 asdhealthcare.com Product Manufacturer Indications Cytogam Cytomegalovirus CSL Behring (800) cslbehring.com cytogam.com Prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart GamaSTAN S/D Intramuscular Immune Globulin (Human) hypermunes.com Hepatitis A post-exposure prophylaxis; rubeola; rubella; varicella Contraindications IgA deficiency with IgA antibodies; anaphylaxis to IgA Patients with isolated IgA deficiency; should not be administered to patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate IM injections Form Available Sizes 50mL 2mL / 10mL vials Labelling for Removal of Pathogenic Prions Viral Safety Process Half-Life (Days) Packaged Product Storage Shelf life From Date of Manufacture Solvent/detergent viral inactivation step; precipitation Renal transplant patients receiving 50-mg/kg doses once daily for first 3 days posttransplant followed by once every 21 days for 4 months: 5 13 days during first 2 months posttransplant and days during third to fifth month posttransplant; CMV antibody detectable for up to 2 months following last dose 2 8 C (36 46 F) Potency 50 ± 10 mg / ml Protein Concentration Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Precipitation; depth filtration; solvent / detergent treatment; the final container incubation step used during the manufacture of the product contributes to virus inactivation Unknown; the half-life of IgG in the circulation of individuals with normal IgG levels is 23 days 36 months 5% 15 18% How Supplied Single-dose vial Preservative (thimerosol)-free, latex-free single dose vials Administration IV through a 15µ in-line filter and IVAC pump or equivalent IM administration only Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.
3 HepaGAM B Hepatitis B Immune Globulin Emergent (800) emergentbiosolutions.com hepagamb.com HyperHEP B S/D Hepatitis B Immune Globulin hypermunes.com Prevention of Hepatitis B recurrence following liver transplantation in HBsAg-positive liver transplant patients; hepatitis B post exposure prophylaxis of: acute exposure to blood containing HBsAg; perinatal exposure of infants born to HbsAg-positive mothers; sexual exposure to an HBsAg-positive person; household exposure to persons with acute HBV infection Anaphylactic or severe systemic reactions to human globulins; IgA deficiency with increased risk of anaphylactic reaction; IM injections 1mL, 5mL Solvent/detergent virus inactivation step; chromatography; virus filtration Post-exposure prophylaxis of: acute exposure to blood containing HBsAg; perinatal exposure of infants born to HbsAg-positive mothers; sexual exposure to an HBsAg-positive person; household exposure to persons with acute HBV infection None known; should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations; epinephrine should be available; in patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Hepatitis B Immune Globulin (Human) should be given only if the expected benefits outweigh the risks 0.5mL, 1mL syringes; 1mL, 5mL vials Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Precipitation; depth filtration; solvent / detergent treatment; the final container incubation step used during the manufacture of the product contributes to virus inactivation Mean values for half-life were between 17.5 and 25 days, with the shortest being 5.9 days and the longest 35 days 36 months 36 months Minimum of >312 IU / ml; the measured potency of each lot is stamped on the vial label 5% 15 18% Minimum of 220 IU / ml Single-dose vial IV using an infusion pump; IM Preservative (thimerosol)-free and latex-free vials and syringes IM administration only; 0.06 ml / kg of body weight (refer to the package insert for complete prescribing details) While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.
4 asdhealthcare.com Product Manufacturer Nabi-HB Hepatitis B Immune Globulin Biotest Pharmaceuticals (800) biotestpharma.com HyperRAB S/D Rabies Immune Globulin hypermunes.com Indications Contraindications Treatment of acute exposure to blood containing HBsAg; perinatal exposure of infants born to HBsAg-positive mothers; sexual exposure to HBsAg-positive persons; household exposure to persons with acute HBV infection Anaphylaxis to IG; anaphylaxis to IgA; IgA deficiency with IgA antibodies Form Available Sizes 1mL, 5mL 2mL, 10mL vials Labelling for Removal of Pathogenic Prions Viral Safety Process Precipitation of cohn fraction III; cuno filtration; solvent / detergent virus inactivation step; nanofiltration Rabies post-exposure prophylaxis None known; should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations; the attending physician who wishes to administer HyperRAB S/D to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions; such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA; as with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Precipitation; depth filtration; solvent / detergent treatment; the final container incubation step used during the manufacture of the product contributes to virus inactivation Half-Life (Days) 23.1 ± 5.5 days Unknown; detectable passive rabies antibody titers were observed in the serum by 24 hours post injection and persisted for 21 days, following the IM administration of 20 IU / kg Packaged Product Storage Shelf life From Date of Manufacture Potency Protein Concentration 39 months 36 months 1mL dose: >312 IU; 5mL dose: > 1560 IU 5 ± 1% 15 18% Average 150 IU / ml How Supplied Single-dose vial Preservative (thimerosol)-free and latex-free single dose vials Administration IM administration only IM administration only; ml / kg of body weight Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.
5 Rabies post exposure prophylaxis IMOGAM Rabies-HT Rabies Immune Globulin Sanofi Pasteur (800) sanofipasteur.us Tetanus post-exposure prophylaxis HyperTET S/D Tetanus Immune Globulin hypermunes.com Do not administer in repeated doses once vaccine treatment has been initiated; repeating the dose may interfere with maximum active immunity expected from the vaccine None known; should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations; in patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HyperTET S / D should be given only if the expected benefits outweigh the risks 2mL Cold alcohol fractionation; heat-treatment 60 C 10 hrs; precipitation III stage of manufacturing 250 unit prefilled disposable syringe Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Precipitation; depth filtration; solvent/detergent treatment; the final container incubation step used during the manufacture of the product contributes to virus inactivation Unknown; the half-life of IgG in the circulation of individuals with normal IgG levels is 23 Days 36 months 150 IU / ml Minimum of 250 AU (anti-toxin units) / syringe 10 18% 15 18% Vial For wound infiltration and intramuscular administration only; the recommended dose is 20 IU / kg (0.133 ml / kg) or 9 IU / lb (0.06 ml/lb) of body weight administered at the time of the first vaccine dose Preservative (thimerosol)-free, in a latex-free delivery system IM administration only (refer to the package insert for complete prescribing details) While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.
6 asdhealthcare.com Product Manufacturer HyperRho S/D (D) Immune Globulin RhoGAM Ultra-Filtered PLUS (D) Immune Globulin Kedrion BioPharma, Inc. (855) kedrion.com rhogam.com Indications Contraindications For prevention of isoimmunization and prevention of Rh hemolytic disease of the newborn (refer to the package insert for complete prescribing details) None known; Rho(D) Immune Globulin (Human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations; the attending physician who wishes to administer Rho(D) Immune Globulin (Human) to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions; such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA; as with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders. Form Concentration 15 18% 300 μg Available Sizes Labelling for Removal of Pathogenic Prions Viral Removal Method Mini-Dose: 250 IU prefilled disposable syringe in 10pk; Full Dose: 1500 IU prefilled disposable syringe in 10pk and single syringe Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Precipitation; depth filtration; solvent / detergent treatment; the final container incubation step used during the manufacture of HyperRHO S / D contributes to virus inactivation Rh Isoimmunization supression Rh IU IgA Conent <15 μg / dose Fractionation; filtration; inactivation Stabilizer Glycine Glycine; polysorbate 80 Sugar Content Sodium Content 2.9 mg / ml ph Osmolality (m0sm/kg) Half-Life (days) Unknown; the half-life of IgG in the circulation of individuals with normal IgG levels is approximately 23 to 26 Days Storage 2 8 C; 2 8 C; Shelf-Life 36 months 24 months Reconstitution Fluid/Diluent N/A Administration IM administration only Intramuscular only 31 Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.
7 Rhophylac (D) Immune Globulin CSL Behring cslbehring.com rhophylac.com Adults with chronic ITP; Rh Isoimmunization suppression Anaphylaxis to IG; selective IgA deficiency with IgA antibodies and hypersensitivity; do not administer to newborn of a mother that received Rhophylac postpartum WinRho SDF (D) Immune Globulin Emergent (800) hepagamb.com emergentbiosolutions.com Children with chronic or acute ITP; adults with chronic ITP; children and adults with ITP secondary to HIV infection; Rh Isoimmunization suppression Infant for suppression of Rh isoimmunization; anaphylaxis to IG; IgA deficiency; history of autoimmune hemolytic anemia, preexisting hemolysis, or high risk of hemolysis (ready-to-use) 300 μg (1500 IU) 300 / 500 / 1000 / 3000 μg 2 ml prefilled syringe 1500 / 2500 / 5000 / IU Vials Solvent / detergent; nanofiltration Sovent / detergent; planova 20 N viral filtration; ion exchange chromatography <5 μg / ml 5 μg / ml Albumin Maltose; polysorbate M 10% Maltose IV 16 ± 4; IM 18 ± C; months 36 months 2 8 C; Idiopathic Thrombocytopenic Purpura IV only; Rh Isoimmunization Suppression IV or Intramuscular; Idiopathic Thrombocytopenic Purpura: 2mL / sec Idiopathic Thrombocytopenic Purpura IV only; Rh Isoimmunization Suppression IV or Intramuscular While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.
8 Others asdhealthcare.com aspire. ASD Healthcare delivers. When you re in the business of saving lives, you depend on exceptional customer service from your healthcare partners. So when you want a life-saving medication within hours, or need an extensive range of plasma-derived and recombinant therapeutics, connect with ASD Healthcare. Our people are here to help you get the products you need, when you need them. That s standard business for us, a part of our True Blue culture that makes going the extra mile an ordinary part of our day. Others aspire to meet our exceptional service. ASD Healthcare simply delivers. Convenient Connection ASD Healthcare makes it easy to order and reorder your inventory any time, any day, anywhere. Connect at Customer Service Emergency on-call phone orders 365 / 24 / 7 Expedited orders for same-day delivery in 48 states Expertise and resources for access to critical care products Your Patients. Your Purpose. Our Priority.
Immunologic Products asdhealthcare.com
Immunologic Products Bivigam Carimune NF Flebogamma DIF Gammagard S/D Low IGA Gammagard Liquid Gammaked Gammaplex Gamunex -C Hizentra HyQvia Octagam Privigen Immunologic Products 800.746.6273 asdhealthcare.com
More informationImmune Globulin Comparison Table
I. Formulation data Gamunex /IGIVnex Gammagard Liquid Privigen Vivaglobin Formulation Lyophilized Liquid Liquid Liquid Liquid Concentration 5% or 10% upon reconstitution Administration set provided? IgA
More informationHepatitis B Immune Globulin Biological Page
Hepatitis B Immune Globulin Biological Page Section 7: Biological Product Information Standard #: 07.233 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide
More informationHuman Hepatitis B Immunoglobulin, solution for intramuscular injection.
New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF is a sterile,
More informationHuman Zoster Immunoglobulin, solution for intramuscular injection.
Product Information Zoster Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Zoster Immunoglobulin, solution for intramuscular injection. DESCRIPTION Zoster Immunoglobulin-VF is a sterile, preservative-free
More informationIMOGAM RABIES PASTEURIZED - HUMAN RABIES IMMUNOGLOBULIN. Active ingredient: Human proteins mg
IMOGAM RABIES PASTEURIZED - HUMAN RABIES IMMUNOGLOBULIN COMPOSITION 1 ml of human rabies immunoglobulin contains: Active ingredient: Human proteins 100 180 mg containing (IgG class) human rabies immunoglobulins
More informationTetanus Immune Globulin (Human) Biological Page
Tetanus Immune Globulin (Human) Biological Page Section 7: Biological Product Information Standard #: 07.322 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide
More informationHuman Normal Immunoglobulin, solution for intramuscular injection.
Product Information Normal Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Normal Immunoglobulin, solution for intramuscular injection. DESCRIPTION Normal Immunoglobulin-VF is a sterile, preservative-free
More informationBlood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
New Zealand Data Sheet 1 PRODUCT NAME HyperHEP B Hepatitis B Immunoglobulin (Human) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Hepatitis B Immunoglobulin, USP Glycine, USP Water for injection,
More informationAPEC Guidelines Immunizations
Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should
More informationDATA SHEET RHESONATIV. NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection
DATA SHEET RHESONATIV NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection DESCRIPTION Rhesonativ contains 625 IU of human anti-d immunoglobulin. Rhesonativ is presented as a solution for
More informationKEDRAB Rabies Immune Globulin (Human) Solution for intramuscular injection Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEDRAB safely and effectively. See full prescribing information for KEDRAB. KEDRAB Rabies Immune
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT UMAN BIG 180 IU/ml Solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. UMAN BIG 180 IU/1
More informationHepatitis B Immune Globulin (Human)
14-7636-003 (Rev. October 2000) Hepatitis B Immune Globulin (Human) BayHep B Solvent/Detergent Treated DESCRIPTION Hepatitis B Immune Globulin (Human) BayHep B treated with solvent/detergent is a sterile
More information1. TRADE NAME OF THE MEDICINAL PRODUCT
1. TRADE NAME OF THE MEDICINAL PRODUCT IGANTET 250 I.U. solution for injection in pre-filled syringe IGANTET 500 I.U. solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationBDI Pharma, LLC 2018 Product Reference Charts
BDI Pharma, LLC 2018 Product Reference Charts Protein Therapies Intravenous Immune Globulin (10%) 800.948.9834 www.bdipharma.com BIVIGAM NF ADMA Biologics Flebogamma 10% DIF GAMMAGARD LIQUID Gammaked Kedrion
More informationPATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER
Verified with regard to factual content 13.12.2011 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER GAMMA anty-hbs 1000 Immunoglobulinum humanum hepatitidis B Human immunoglobulin against Hepatitis
More informationIndication Dosage Instruction Measles 0.25 ml/kg Administer within 6 days of exposure.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAMASTAN safely and effectively. See full prescribing information for GAMASTAN. GAMASTAN (immune
More informationHuman plasma protein 50 mg/ml of which at least 96% is IgG, with a content of antibodies to Hepatitis B virus surface antigen (HBs) of 50 IU/ml
Hepatect CP 1. NAME OF THE MEDICINAL PRODUCT Hepatect CP 50 IU/ml; solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. Human plasma protein 50 mg/ml of which
More informationKnow your IVIg options for primary immunodeficiency
Please see full on following page Please see full prescribing information for Privigen, including boxed warning, in pocket. Please see full above See full prescribing information for full boxed warning.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Rhophylac 300 micrograms / 2 ml, solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled
More informationFor platelet control as individual as you
For platelet control as individual as you Explore the possibilities of Immune Thrombocytopenic Purpura (ITP) treatment. Important Risk Information WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis
More informationSubcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency
Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency EDUCATIONAL OBJECTIVES Upon completion of this program, participants should be better able to: 1.
More informationCangene Corporation Page 1 of 12
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VARIZIG safely and effectively. See full prescribing information for VARIZIG. VARIZIG [Varicella
More informationInformation for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print
Information for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print Composition 1 ml solution contains: Active ingredients:. plasma proteins
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN
More informationNEW ZEALAND DATA SHEET
1 PRODUCT NAME Normal Immunoglobulin-VF, 160 mg/ml, solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human Normal Immunoglobulin Normal Immunoglobulin-VF is a sterile solution with no
More informationQuick Reference: Plasma Protein Products
All plasma protein products a contraindicated in patients with any of the following: Hypersensitivity to the product or any ingdient in the formulation or component of the container. Pvious anaphylactic
More information1 WHAT OCTAGAM 50 mg/ml IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER Octagam 50 mg/ml, solution for infusion Human Normal Immunoglobulin (IVIg) Read all of this leaflet carefully before you start using this medicine. - Keep this
More informationNEW ZEALAND DATA SHEET
1 PRODUCT NAME Rh(D) Immunoglobulin-VF 250 IU, solution for intramuscular injection Rh(D) Immunoglobulin-VF 625 IU, solution for intramuscular injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human
More informationJvD/PL/ PACKAGE LEAFLET
JvD/PL/20160721 1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER GammaQuin, 160 g/l, solution for injection Human normal immunoglobulin Read all of this leaflet carefully before you start using
More informationCSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1
Page 1 CSL Behring Albuminar -25 Albumin (Human) USP, 25% R x only DESCRIPTION Albuminar -25, Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous
More informationThe Role of Anti-D in the Management of Chronic and Secondary Forms of ITP
The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP 473 82 The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP MAURICE GILLES GENEREUX BACKGROUND Immune thrombocytopenic
More informationPRODUCT MONOGRAPH. HepaGam B
PRODUCT MONOGRAPH HepaGam B Hepatitis B Immune Globulin (Human) Injection Liquid >312 IU/mL Standard: World Health Organization (WHO) International Reference Preparation Passive Immunizing Agent HepaGam
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. Name of the product: 1.1 Product name: EQUIRAB Rabies Antiserum - Equine 1.2 Strength: 1000 I.U. / 5 ml 1.3 Pharmaceutical Dosage form: Injection 2. Qualitative and
More informationClinical Policy: Immune Globulins Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid
Clinical Policy: Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy
More informationPHARMACOPOEIA MONOGRAPH
MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Human coagulation factor IX PHARMACOPOEIA MONOGRAPH PM.3.3.2.0004.15 First Edition The present Pharmacopoeia Monograph applies to human coagulation factor IX
More informationIVIg. Treatment With Privigen. Proven protection Designed for stability. Your guide to USED IN US HOSPITALS SINCE 2010
# 1 IVIg USED IN US HOSPITALS SINCE 2010 Your guide to Treatment With Privigen For people with primary immunodeficiency (PI) Proven protection Designed for stability Please see full Important Safety Information
More informationSV/SPC/ SUMMARY OF PRODUCT CHARACTERISTICS
SV/SPC/20160315 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GammaQuin 160 g/l solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg)
More information(English translation of official Dutch version) PACKAGE LEAFLET JK/PL/
(English translation of official Dutch version) PACKAGE LEAFLET JK/PL/20160914 1 Package leaflet: Information for the user TetaQuin 250 IU solution for injection Human tetanus immunoglobulin Read all of
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN TETANUS IMMUNOGLOBULIN FOR INTRAMUSCULAR USE (CPMP/BPWG/3730/02)
European Medicines Agency Human Medicines Evaluation Unit London, 27 July 2005 CPMP/BPWG/3730/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN TETANUS IMMUNOGLOBULIN FOR INTRAMUSCULAR
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GAMMANORM, 165 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg) Human
More informationSUMMARY OF PRODUCT CHARACTRISTICS
1. NAME OF THE MEDICINAL PRODUCT Purified, Inactivated, Lyophilized Rabies Vaccine, Prepared on Vero Cells INDIRAB 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Qualitative Formula per dose of 0.5 ml (Single
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Human Medicines Evaluation Unit London, 27 April 2006 CPMP/BPWG/4027/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CORE SPC FOR HUMAN PLASMA DERIVED
More informationGammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin
PACKAGE LEAFLET: INFORMATION FOR THE USER Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationApplicant (Invented) Name Strength Pharmaceutical Form. UMAN BIG 180 I.E./ml Injektionslösung. UMAN BIG 180 IU/ml Solution for injection
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS AND MARKETING AUTHORISATION HOLDER IN THE MEMBER STATE 1 Member State EU/EEA Marketing
More informationPRODUCT MONOGRAPH. GamaSTAN S/D. Immune Globulin (Human) Solvent/Detergent Treated. Injectable Solution, 15-18% Protein. Manufacturer s Standard
PRODUCT MONOGRAPH GamaSTAN S/D Immune Globulin (Human) Solvent/Detergent Treated Injectable Solution, 15-18% Protein Manufacturer s Standard Passive Immunizing Agent Manufactured by: Grifols Therapeutics
More informationFor platelet control as individual as you
For platelet control as individual as you Explore the possibilities of Immune Thrombocytopenic Purpura (ITP) treatment. Important Risk Information WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis
More informationConsiderations for Tetanus While Treating an Exposure to Rabies
Considerations for Tetanus While Treating an Exposure to Rabies Since rabies and tetanus are not as common in the United States (US) as they used to be, 1,2 people may not be fully aware of these diseases
More informationEVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3
EVOGAM Information for patients 11179 Evogam NZ Patient Brochure Update FA3 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have been
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WinRho SDF safely and effectively. See full prescribing information for WinRho SDF. WinRho SDF [Rh
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CORE SPC FOR HUMAN ANTI-D IMMUNOGLOBULIN FOR INTRAVENOUS USE Revision 1
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 20 September 2007 CHMP/BPWP/319619/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE
More informationCONSUMER MEDICINE INFORMATION LEAFLET
CONSUMER MEDICINE INFORMATION LEAFLET Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask
More informationThe University of Mississippi Medical Center The University of Mississippi Health Care. Pharmacy and Therapeutics Committee Medication Use Evaluation
The University of Mississippi Medical Center The University of Mississippi Health Care Pharmacy and Therapeutics Committee Medication Use Evaluation June 2012 Objective The goal of this medication use
More informationPackage leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration
: Information for the user HEPATECT CP 50 IU/ml solution for infusion Human hepatitis B immunoglobulin for intravenous administration Read all of this leaflet carefully before you start using this medicine
More informationCOMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)
COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH) CLUVOT 250 IU Rev.: 08-MAY-2014 / New license CSL Behring Page 1 of 10 Package leaflet: Information for the user Powder and solvent for solution for injection/infusion.
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationInfusion of intravenous gamma globulin (immunoglobulins)
Infusion of intravenous gamma globulin (immunoglobulins) OBJECTIVES Intravenous gamma globulin therapy is indicated for replacement therapy in patients with primary and secondary antibody deficiency syndromes.
More informationMichigan Guidelines: HIV, Syphilis, HBV in Pregnancy
Michigan Guidelines: HIV, Syphilis, HBV in Pregnancy Presenter: Theodore B. Jones, MD Maternal Fetal Medicine Wayne State University School of Medicine Beaumont Dearborn Hospital HIV, Syphilis, HBV in
More informationPNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients
For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients PNH ahus Dosing and Administration Soliris is indicated for the treatment of patients with paroxysmal
More informationEVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11
EVOGAM Information for patients 11881 Evogam 2014 NZ Patient Brochure Update v11 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have
More informationImmunization. Historical point
Immunization Historical point In 1796 Edward Jenner s use of material from cowpox pustules to provide protection against smallpox. Louis Pasteur s 1885 rabies was the next to make an impact on human disease
More information09/17/2018. Standing Order for Influenza Vaccine for SKIIP Participants
Purpose: To reduce the morbidity and mortality of influenza by vaccinating those children and adolescents who meet the criteria established by the Centers for Disease Control and Prevention s (CDC) Advisory
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationD-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin
Package leaflet: Information for the patient D-Gam 50 micrograms/ml D-Gam 250 micrograms/ml Solution for injection human anti-d immunoglobulin Read all of this leaflet carefully before you start using
More informationMagdy El Ekiaby, MD Shabrawishi Hospital BTC & HTC Cairo, Egypt
Magdy El Ekiaby, MD Shabrawishi Hospital BTC & HTC Cairo, Egypt Are plasma and cryoprecipitate still used? They are still largely used for treatment of hereditary bleeding disorders in many resource limited
More informationSandoglobulin. Product Information. Australia NAME OF THE MEDICINE. Human normal immunoglobulin for intravenous injection DESCRIPTION
Product Information Sandoglobulin Australia NAME OF THE MEDICINE Human normal immunoglobulin for intravenous injection DESCRIPTION Sandoglobulin is a sterile, lyophilised preparation for reconstitution,
More informationSubcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Mai Thị Bích Ngọc
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases Mai Thị Bích Ngọc Background Primary immunodeficiency diseases (PIDD): group of over 150 disorders
More informationSodium chloride and sodium acetate corresponding to sodium Polysorbate µg Water for Injections 82.5 micrograms
PRODUCT INFORMATION gammanorm NAME OF DRUG gammanorm, Human Normal Immunoglobulin (SC/IMIg), 165 mg/ml, solution for intramuscular injection or subcutaneous infusion One vial of 10 ml gammanorm contains
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRUMENBA safely and effectively. See full prescribing information for TRUMENBA. TRUMENBA (Meningococcal
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) I.P. Injectable, Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.5 ml contains:
More informationPNH ahus gmg. Dosing and Administration Guide
Injection for Intravenous Use PNH ahus gmg For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus), and generalized Myasthenia Gravis (gmg) patients Dosing and Administration
More information1. QUALITATIVE AND QUANTITATIVE COMPOSITION
INFANRIX 1. QUALITATIVE AND QUANTITATIVE COMPOSITION contains diphtheria toxoid, tetanus toxoid, and three purified pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and 69 kilodalton
More informationPrimary Diagnosis: Diagnosis Code(s) (if known): Individual s Weight (lbs) (kg)
Request Date: Initial Request Buy and Bill Individual s Name: Insurance Identification Number: Subsequent request Date of Birth: Individual s Phone Number: Primary Diagnosis: Diagnosis Code(s) (if known):
More informationNew Advances in Transfusion EM I LY CO BERLY, M D
New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for
More informationSummary of product characteristics As per Annexure C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1
Summary of product characteristics As per Annexure C SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1 1. NAME OF THE MEDICINAL PRODUCT. ANNEXURE C to MODULE I Measles, Mumps & Rubella Vaccine
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationTWINRIX GlaxoSmithKline
TWINRIX GlaxoSmithKline 1. Name of medicinal product Twinrix 2. Qualitative and quantitative composition Twinrix is a combined vaccine formulated by pooling bulk preparations of the purified, inactivated
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Nanogam is intended to be used for the treatment of diseases in patients who are suffering from a shortage of immunoglobulins
More informationNormal Immunoglobulin (Human) 16%, solution for subcutaneous administration.
Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain
More informationClinical Policy: Immune Globulins Reference Number: ERX.SPMN.129
Clinical Policy: Immune Globulins Reference Number: ERX.SPMN.129 Effective Date: 03/14 Last Review Date: 09/16 Revision Log Coding_Implications See Important Reminder at the end of this policy for important
More informationDrug Class Prior Authorization Criteria Immune Globulins
Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of
More informationIMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL
PRIMARY IMMUNODEFICIENCIES IMMUNOGLOBULINS: ONE SIZE DOESN T FIT ALL IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL 1 PRIMARY IMMUNODEFICIENCIES ABBREVIATIONS IG IPOPI IV PID SC Immunoglobulins
More informationIVD information *Droppers for the sensitized and control cells. Not for use other than dispensing the sensitized and control cells.
In Vitro Diagnostic Reagent Instruction Manual of Diagnostic Reagent for Determination of anti-hbs Thoroughly read this instruction manual before use of this kit Background of the development and features
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationHuman Cytomegalovirus Immunoglobulin, solution for intravenous injection.
Product Information CMV Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Cytomegalovirus Immunoglobulin, solution for intravenous injection. DESCRIPTION CMV Immunoglobulin-VF is a sterile, preservative
More informationHepatitis B Vaccine: ENGERIX -B
Hepatitis B Vaccine: ENGERIX -B Revision Date: August 25, 2016 Rationale for Policy Update: Incorporated updated CIG and ACIP recommendations for immune compromised individuals and those with renal disease.
More informationSCIG: (Immune globulin SQ) Hizentra, Vivaglobin, Gammagard Liquid, Gamunex- C, Gammaked, Hyqvia Page 1 of 6
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 04/1 Revision Date(s): 02/16 Developed By: Medical Criteria Committee Effective Date: 0/01/1 SCIG: (Immune globulin SQ) Hizentra,
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationin pregnancy Document Review History Version Review Date Reviewed By Approved By
GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:
More informationIMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe
IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe Read all of this leaflet carefully before you are vaccinated or before you have your child vaccinated. Keep
More informationTwinrix Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed)
Twinrix Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed) QUALITATIVE AND QUANTITATIVE COMPOSITION Suspension for injection. One dose (1.0 ml) contains: Hepatitis A virus (inactivated) 1,2
More information09/07/2017. Standing Order for Influenza Vaccine for SKIIP Participants
Purpose: To reduce the morbidity and mortality of influenza by vaccinating those children and adolescents who meet the criteria established by the Centers for Disease Control and Prevention s (CDC) Advisory
More informationHepatitis B in Travellers
Hepatitis B in Travellers Please find product Prescribing Information at the end of this presentation Hepatitis B A serious blood-borne liver infection, which can cause both acute and chronic disease 1,2
More informationWHO Recommendations and Guidelines for the Prevention of Perinatal Hepatitis B and Use of Hepatitis B Vaccines
WHO Recommendations and Guidelines for the Prevention of Perinatal Hepatitis B and Use of Hepatitis B Vaccines Steven Wiersma,, Medical Officer WHO/EPI EPI,, Geneva March, 2006 Epidemiology Strategy WHO
More informationDocument is provided for sample purposes only. Content is not updated and should not be used for traveler counseling.
Hepatitis A Medical Summary Note: This article also contains information on the combination hepatitis A-hepatitis B (HepA-HepB) vaccine. What's New Hepatitis A (HepA) vaccination is now recommended by
More information